MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
IPO Year: 2014
Exchange: NASDAQ
Website: mediwound.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $34.00 | Outperform | Oppenheimer |
| 5/2/2025 | $25.00 | Buy | Alliance Global Partners |
| 2/28/2025 | $39.00 | Buy | Craig Hallum |
| 7/16/2024 | $25.00 → $30.00 | Buy | Maxim Group |
| 12/22/2022 | $11.00 | Buy | Maxim Group |
| 7/18/2022 | $7.00 | Outperform | Oppenheimer |
| 8/17/2021 | $10.00 → $9.00 | Buy | Aegis Capital |
| 8/11/2021 | $7.00 → $6.50 | Buy | HC Wainwright & Co. |
6-K - MediWound Ltd. (0001593984) (Filer)
6-K - MediWound Ltd. (0001593984) (Filer)
6-K - MediWound Ltd. (0001593984) (Filer)
424B3 - MediWound Ltd. (0001593984) (Filer)
EFFECT - MediWound Ltd. (0001593984) (Filer)
F-3 - MediWound Ltd. (0001593984) (Filer)
S-8 - MediWound Ltd. (0001593984) (Filer)
20-F - MediWound Ltd. (0001593984) (Filer)
6-K - MediWound Ltd. (0001593984) (Filer)
6-K - MediWound Ltd. (0001593984) (Filer)